IDEX BIOMETRICS ASA (IDEX.OL) Stock Fundamental Analysis
Europe - OSL:IDEX - NO0013536078 - Common Stock
2.8 NOK
-0.13 (-4.44%)
Taking everything into account, IDEX scores 1 out of 10 in our fundamental rating. IDEX was compared to 53 industry peers in the Electronic Equipment, Instruments & Components industry. IDEX has a bad profitability rating. Also its financial health evaluation is rather negative. IDEX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
IDEX had negative earnings in the past year.
In the past year IDEX has reported a negative cash flow from operations.
IDEX had negative earnings in each of the past 5 years.
In the past 5 years IDEX always reported negative operating cash flow.
1.2 Ratios
IDEX's Return On Assets of -100.76% is on the low side compared to the rest of the industry. IDEX is outperformed by 92.45% of its industry peers.
IDEX has a worse Return On Equity (-931.96%) than 90.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -100.76% | ||
| ROE | -931.96% | ||
| ROIC | N/A |
ROA(3y)-119.85%
ROA(5y)-118.87%
ROE(3y)-228.17%
ROE(5y)-196.92%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for IDEX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IDEX does not have a ROIC to compare to the WACC, probably because it is not profitable.
IDEX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IDEX has more shares outstanding
Compared to 1 year ago, IDEX has an improved debt to assets ratio.
2.2 Solvency
IDEX has an Altman-Z score of -3.90. This is a bad value and indicates that IDEX is not financially healthy and even has some risk of bankruptcy.
IDEX has a Altman-Z score of -3.90. This is amonst the worse of the industry: IDEX underperforms 90.57% of its industry peers.
A Debt/Equity ratio of 1.75 is on the high side and indicates that IDEX has dependencies on debt financing.
The Debt to Equity ratio of IDEX (1.75) is worse than 86.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.75 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.9 |
ROIC/WACCN/A
WACC8.21%
2.3 Liquidity
IDEX has a Current Ratio of 1.67. This is a normal value and indicates that IDEX is financially healthy and should not expect problems in meeting its short term obligations.
IDEX has a Current ratio (1.67) which is comparable to the rest of the industry.
A Quick Ratio of 0.47 indicates that IDEX may have some problems paying its short term obligations.
IDEX has a Quick ratio of 0.47. This is amonst the worse of the industry: IDEX underperforms 86.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.67 | ||
| Quick Ratio | 0.47 |
3. Growth
3.1 Past
IDEX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.99%, which is quite impressive.
Looking at the last year, IDEX shows a very negative growth in Revenue. The Revenue has decreased by -87.72% in the last year.
The Revenue has been growing by 14.73% on average over the past years. This is quite good.
EPS 1Y (TTM)92.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-250%
Revenue 1Y (TTM)-87.72%
Revenue growth 3Y-33.35%
Revenue growth 5Y14.73%
Sales Q2Q%-79.49%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year49.24%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IDEX. In the last year negative earnings were reported.
IDEX is valuated cheaply with a Price/Forward Earnings ratio of 5.39.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IDEX indicates a rather cheap valuation: IDEX is cheaper than 92.45% of the companies listed in the same industry.
IDEX is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.27, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.39 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
IDEX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:IDEX (11/5/2025, 10:04:23 AM)
2.8
-0.13 (-4.44%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)
Earnings (Next)
Inst Owners4.78%
Inst Owner ChangeN/A
Ins Owners37.78%
Ins Owner ChangeN/A
Market Cap49.13M
Revenue(TTM)269.00K
Net Income(TTM)-8574000
Analysts82.86
Price Target1148.1 (40903.57%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)9899.97%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.39 | ||
| P/S | 17.9 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.23 | ||
| P/tB | 12.07 | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.14
EYN/A
EPS(NY)0.52
Fwd EY18.54%
FCF(TTM)-5.72
FCFYN/A
OCF(TTM)-5.72
OCFYN/A
SpS0.16
BVpS0.54
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -100.76% | ||
| ROE | -931.96% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-119.85%
ROA(5y)-118.87%
ROE(3y)-228.17%
ROE(5y)-196.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.75 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.67 | ||
| Quick Ratio | 0.47 | ||
| Altman-Z | -3.9 |
F-Score2
WACC8.21%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-250%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-87.72%
Revenue growth 3Y-33.35%
Revenue growth 5Y14.73%
Sales Q2Q%-79.49%
Revenue Next Year49.24%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1659.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y67.27%
OCF growth 3YN/A
OCF growth 5YN/A
IDEX BIOMETRICS ASA / IDEX.OL FAQ
What is the ChartMill fundamental rating of IDEX BIOMETRICS ASA (IDEX.OL) stock?
ChartMill assigns a fundamental rating of 1 / 10 to IDEX.OL.
Can you provide the valuation status for IDEX BIOMETRICS ASA?
ChartMill assigns a valuation rating of 2 / 10 to IDEX BIOMETRICS ASA (IDEX.OL). This can be considered as Overvalued.
Can you provide the profitability details for IDEX BIOMETRICS ASA?
IDEX BIOMETRICS ASA (IDEX.OL) has a profitability rating of 0 / 10.